Soligenix Inc. (NASDAQ:SNGX) – Zacks Investment Research increased their FY2017 earnings per share (EPS) estimates for Soligenix in a note issued to investors on Monday. Zacks Investment Research analyst G. Zeng now forecasts that the biopharmaceutical company will post earnings per share of ($1.30) for the year, up from their previous forecast of ($1.50).

Soligenix (NASDAQ:SNGX) last announced its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.15. The firm had revenue of $1.82 million during the quarter, compared to analyst estimates of $1.36 million. Soligenix had a negative return on equity of 112.81% and a negative net margin of 90.93%.

COPYRIGHT VIOLATION WARNING: “FY2017 EPS Estimates for Soligenix Inc. Raised by Zacks Investment Research (SNGX)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/11/11/fy2017-eps-estimates-for-soligenix-inc-raised-by-zacks-investment-research-sngx.html.

SNGX has been the subject of a number of other reports. Maxim Group set a $4.00 price objective on Soligenix and gave the stock a “buy” rating in a research report on Thursday, July 27th. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Soligenix in a research report on Thursday, September 21st.

Shares of Soligenix (NASDAQ:SNGX) opened at $2.15 on Thursday. Soligenix has a 12-month low of $1.74 and a 12-month high of $5.08.

Soligenix Company Profile

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Receive News & Stock Ratings for Soligenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix Inc. and related stocks with our FREE daily email newsletter.